CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma

Peter Herhaus, Jana Lipková, Felicitas Lammer, Igor Yakushev, Tibor Vág, Julia Slotta‐Huspenina, Stefan Habringer, Constantin Lapa, Tobias Pukrop, D. Hellwig, Benedikt Wiestler, Andreas K. Buck, Martina Deckert, Hans‐Jürgen Wester, Florian Bassermann, Markus Schwaiger, Wolfgang Weber, Bjoern Menze, Ulrich KellerJournal of Nuclear Medicine 2020 · DOI

Abstract

C-X-C chemokine receptor 4 (CXCR4) is a transmembrane chemokine receptor involved in growth, survival, and dissemination of cancer, including aggressive B-cell lymphoma. MRI is the standard imaging technology for central nervous system (CNS) involvement of B-cell lymphoma and provides high sensitivity but moderate specificity. Therefore, novel molecular and functional imaging strategies are urgently required. Methods: In this proof-of-concept study, 11 patients with lymphoma of the CNS (8 primary and 3 secondary involvement) were imaged with the CXCR4-directed PET tracer $^{68}$Ga-pentixafor. To evaluate the predictive value of this imaging modality, treatment response, as determined by MRI, was correlated with quantification of CXCR4 expression by $^{68}$Ga-pentixafor PET in vivo before initiation of treatment in 7 of 11 patients. Results: $^{68}$Ga-pentixafor PET showed excellent contrast with the surrounding brain parenchyma in all patients with active disease. Furthermore, initial CXCR4 uptake determined by PET correlated with subsequent treatment response as assessed by MRI. Conclusion: $^{68}$Ga-pentixafor PET represents a novel diagnostic tool for CNS lymphoma with potential implications for theranostic approaches as well as response and risk assessment.

Introduction

Central Nervous System Lymphoma (CNSL) is a rare but aggressive malignancy. Currently, clinicians rely on contrast-enhanced MRI for diagnosis and monitoring. However, MRI offers only moderate specificity, sometimes making it difficult to distinguish lymphoma from other brain tumors like glioblastoma, and can be unreliable when determining if a patient has reached complete remission. While $^{18}$F-FDG PET is a standard in oncology, it performs poorly in the brain due to high background glucose consumption in healthy tissue. This study explores a novel molecular imaging approach using $^{68}$Ga-pentixafor, a PET tracer that targets the CXCR4 receptor, which is frequently overexpressed in aggressive B-cell lymphomas.

Methods

This proof-of-concept observational study included 11 patients (8 with primary CNSL and 3 with secondary involvement). Patients underwent PET/CT or PET/MRI scans using $^{68}$Ga-pentixafor, a small peptide with high affinity for CXCR4. Standardized Uptake Values (SUVmax and SUVmean) and tumor-to-background ratios were calculated. To validate the PET signal, immunohistochemistry (IHC) was performed on biopsy samples to confirm CXCR4 and CD20 expression. In 7 patients, pre-treatment PET metrics, such as integrated PET uptake ($∫$PET), were correlated with the reduction in tumor volume observed on follow-up MRIs after methotrexate-based chemotherapy.

Results and Discussion

$^{68}$Ga-pentixafor PET demonstrated a high detection rate, with 10 out of 11 patients (91%) showing clear tracer uptake in MRI-confirmed lesions. The tracer provided an exceptional signal-to-noise ratio because it does not accumulate in healthy brain parenchyma, resulting in a "black background" where the tumor is highly visible. SUVmax values in tumors ranged from 4.2 to 23.3, while background tissue remained very low (SUVmean ~0.01 to 0.2), yielding tumor-to-background ratios as high as 83.0.

Comparison of MRI and 68Ga-Pentixafor-PET imaging across four patients, demonstrating high contrast and specificity of the PET tracer compared to standard MRI sequences.

A key finding was the predictive power of the PET signal. Higher initial CXCR4 uptake, specifically the integrated PET signal ($∫$PET), was strongly associated with a better response to chemotherapy ($p = 0.0005$ in patient-based analysis). This suggests that CXCR4 density may serve as a proxy for tumor vulnerability or aggressive metabolic state, outperforming simple volume measurements from MRI.

Correlation analysis between pre-treatment imaging metrics and treatment efficacy. Panel F highlights the significant correlation between integrated PET uptake and patient-based treatment response.

The study also noted a "steroid effect": one PET-negative patient had received extensive corticosteroid treatment before the scan. Since steroids induce apoptosis in lymphoma cells, they can rapidly diminish the CXCR4 signal, which is a critical consideration for clinical timing. Furthermore, the high uptake observed suggests "theranostic" potential; patients with high CXCR4 expression could be candidates for endoradiotherapy using the therapeutic twin tracer, pentixather.

Conclusion

$^{68}$Ga-pentixafor PET is a highly specific imaging tool for CNS B-cell lymphoma, offering superior contrast to standard glucose-based PET and providing valuable prognostic information. While limited by a small sample size, these results support larger prospective trials to confirm the role of CXCR4 imaging in response assessment and targeted radionuclide therapy.

Summary updated

Abstract

C-X-C chemokine receptor 4 (CXCR4) is a transmembrane chemokine receptor involved in growth, survival, and dissemination of cancer, including aggressive B-cell lymphoma. MRI is the standard imaging technology for central nervous system (CNS) involvement of B-cell lymphoma and provides high sensitivity but moderate specificity. Therefore, novel molecular and functional imaging strategies are urgently required. <b>Methods:</b> In this proof-of-concept study, 11 patients with lymphoma of the CNS (8 primary and 3 secondary involvement) were imaged with the CXCR4-directed PET tracer <sup>68</sup>Ga-pentixafor. To evaluate the predictive value of this imaging modality, treatment response, as determined by MRI, was correlated with quantification of CXCR4 expression by <sup>68</sup>Ga-pentixafor PET in vivo before initiation of treatment in 7 of 11 patients. <b>Results:</b><sup>68</sup>Ga-pentixafor PET showed excellent contrast with the surrounding brain parenchyma in all patients with active disease. Furthermore, initial CXCR4 uptake determined by PET correlated with subsequent treatment response as assessed by MRI. <b>Conclusion:</b><sup>68</sup>Ga-pentixafor PET represents a novel diagnostic tool for CNS lymphoma with potential implications for theranostic approaches as well as response and risk assessment.
BibTeX
@article{herhaus2020cxcr,
  author = {Peter Herhaus and Jana Lipková and Felicitas Lammer and Igor Yakushev and Tibor Vág and Julia Slotta‐Huspenina and Stefan Habringer and Constantin Lapa and Tobias Pukrop and D. Hellwig and Benedikt Wiestler and Andreas K. Buck and Martina Deckert and Hans‐Jürgen Wester and Florian Bassermann and Markus Schwaiger and Wolfgang Weber and Bjoern Menze and Ulrich Keller},
  title = {{CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma}},
  journal = {Journal of Nuclear Medicine},
  year = {2020},
  doi = {10.2967/jnumed.120.241703},
}
Figure